Published: 2020-02-26

A comparative study on concurrent chemoradiation using cisplatin versus carboplatin in the management of locoregionally advanced non-small cell lung cancer

Nithin D. Raj, Sobita D. Yumkhaibam, Srigopal Mohanty, James L. Chongthu, Jaichand S. Laishram


Background: Concurrent chemoradiation is considered the standard care for locoregionally advanced non-small cell lung cancer. This study aimed to compare the treatment response, progression free survival and treatment toxicities between cisplatin and carboplatin based concurrent chemoradiation.

Methods: Between October 2015 and September 2017, 60 eligible patients were enrolled and divided into two arms of 30 patients each. Arm A received EBRT to chest (60Gy/30 fractions) with concurrent weekly Injection Cisplatin 35mg/m2. Arm B received EBRT to chest (60Gy/30 fractions) with concurrent weekly Injection Carboplatin at a dose of AUC-2. Early treatment response was assessed at 1 month and late treatment response at 6 months after completion of radiation using RECIST criteria. Treatment toxicities was assessed using RTOG toxicity criteria. All statistical analysis was carried out using SPSS version 21.

Results: Most patients were in the age range of 61-70 years. Mean age of presentation was 67.53±11.038 years in Arm A and 66.03±12.794 years in Arm B. Median follow up was 16 months for both arms. Response rate of was slightly better in Arm A (73.3% versus 60%). 1 year PFS rate was 53.33% in Arm A and 36.67% in Arm B. Median time to progression was better in Arm A (11 months vs 10 months). Toxicities were almost comparable in both the arms.

Conclusions: Use of carboplatin in combination with radiation therapy is comparable to cisplatin in terms of treatment outcomes with better compliance and lower toxicity.


Carboplatin, Cisplatin, Concurrent chemoradiation, Locoregionally advanced non-small cell lung cancer

Full Text:



Rengan R, Chetty IJ, Decker R, Langer CJ, O’Meara WP, Movsas B. Lung cancer. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady’s Principles And Practice of Radiation Oncology. 6th ed. PA: Lippincott Williams and Wilkins; 2013:938-939.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.

Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83(3):355-67.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics. CA Cancer J Clin. 2008;58(2):71-96.

Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1):21-49.

Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874-81.

Hotta K, Kuira K. Role of platinum based radiochemotherapy for locally advanced non-small cell lung cancer: Possible influence of type of platinum on survival data. Ann Oncol. 2006;17(11):1724.

Marcu LG. Improving Therapeutic ratio in head and neck cancer with adjuvant and Cisplatin based treatments. Biomed Res Int. 2013;817279:1-4.

Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW et al. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013;18(7):843-.9

Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692-9.

Gervais R, Ducolone A, Lechevalier T, Legroumellec A, Lemarie E, Quoix E et al. Conventional radiation with daily carboplatin (Cb) compared to RT alone after induction chemotherapy(ICT) [vinorelbine (Vr)-cisplatin (P)]: Final results of a randomized phase III trial in stage III unresectable non-small cell lung cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol. 2005;23(16):7016-7.

Lechevalier T, Arriagada R, Quoix E, Ruffle P, Martin M, Tarayre M et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomised trial in 353 patients. J Natl Cancer Inst. 1991;83:417-23.

Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC,, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Eng J Med. 1990;323(14):940-5.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899-909.

Pinedo HM, Karim ABMF, van Vliet WH, Snow JB, Vermorken JB. Daily cis-dichlorodiammineplatinum (II) as a radio-enhancer: a preliminary toxicity report. J Cancer Res Clin Oncol. 1983;105:79-82.

Auperin A, Pechoux CL, Pignon JP, Koning C, Jeremic B, Clamon G et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17(3):473-83.

Clamon G, HerndonJ, Eaton W, Rosenman J, Maurer LH, Cooper MR et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: A phase II trial of Cancer and Leukemia Group B. Cancer Invest. 1994;12(3):273- 82.

Patterson CJ, Hocking M, Bond M, Teale C. Retrospective study for lung cancer in patients aged 75 years and over. Age Ageing. 1998;27(4):515-8.

Fairchild A, Harris K, Barnes E, Wong R, Lutz ST, Bezjak A et al. Palliative Thoracic Radiotherapy for Lung Cancer: A Systematic Review. J Clin Oncol. 2008;26(24): 4001-11.

Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52:129-36.

Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998;16:3078-81.

Belderbos J, Uitterhoeve L., van Zandwijk L, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43:114-21.

Pradier O, Lederer K, Hille A, Weiss E, Christiansen H, Schmidberger H et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol. 2005;131:261-9.

Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol. 1995;13:1425-9

Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. J Cancer Res Ther. 2006;2:14-6.

Çakir Ş, Yücel İ , Egehan İ , Küçükpilakçi B , Soylu B, Elgin Y et al. Radiotherapy versus radiotherapy enhanced by cisplatin in inoperable nonmetastatic nonsmall cell lung cancer (NSCLC) : Preliminary Results Of a Randomized Study. Radiother Oncol. 1996;40:S151.

Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524-3.

Gouda YS, Kohail HM, Eldeeb NA, Omar AM, El-Geneidy MM, Elkerm YM. Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with or without prior induction chemotherapy in patients with locally advanced non-small cell lung cancer. J Egypt Natl Canc Inst. 2006;18(1):73-81.

Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al. Sequential versus concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-60.

Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small cell lung cancer: ESMO Clinical practical guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;21(5):103-15.

Trovó MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24(1):11-5.

Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer. 2004;43:309-16.

Ichinose Y, Nakai Y, Kudoh S, Semba H, Yoshida S, Nukiwa T et al. Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004;10:4369-73.

Groen HJ, van der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol. 2004;15:427-32.

Vokes EE, Herndon J.E, Kelley M.J, Cicchetti MG, Ramnath N, Neill H et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and Leukemia Group. B J Clin Oncol. 2007;25:1698-704.